ArticleCancer pathogenesis and therapy2026

An immune exhaustion signature predicts prognosis and identifies patients with diffuse large B-cell lymphoma (DLBCL) who derive preferential benefit from chimeric antigen receptor (CAR)-T cell therapy.

Bo Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.